These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27428433)

  • 61. Superiority of infectivity-based over particle-based methods for quantitation of drug resistant HIV-1 as inocula for cell cultures.
    Tschochner M; Schwingel E; Thein C; Wittmann S; Paatz C; Walter H
    J Virol Methods; 2007 Apr; 141(1):87-96. PubMed ID: 17196267
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection.
    Booth CL; Geretti AM
    J Antimicrob Chemother; 2007 Jun; 59(6):1047-56. PubMed ID: 17449483
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
    Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
    Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
    Jeeninga RE; Keulen W; Boucher C; Sanders RW; Berkhout B
    Virology; 2001 May; 283(2):294-305. PubMed ID: 11336554
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Genotypic resistance mutations to antiretroviral drugs in newly confirmed human immunodeficiency virus infectors in Beijing].
    Ye JR; Guo L; Lu HY; Xin RL; Zeng Y
    Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(21):1453-6. PubMed ID: 21914279
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
    Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
    J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evolutionary Analyses Suggest a Function of MxB Immunity Proteins Beyond Lentivirus Restriction.
    Mitchell PS; Young JM; Emerman M; Malik HS
    PLoS Pathog; 2015 Dec; 11(12):e1005304. PubMed ID: 26658285
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Complementary Assays Reveal a Low Level of CA Associated with Viral Complexes in the Nuclei of HIV-1-Infected Cells.
    Hulme AE; Kelley Z; Foley D; Hope TJ
    J Virol; 2015 May; 89(10):5350-61. PubMed ID: 25741002
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The interferon-inducible GTPase MxB promotes capsid disassembly and genome release of herpesviruses.
    Serrero MC; Girault V; Weigang S; Greco TM; Ramos-Nascimento A; Anderson F; Piras A; Hickford Martinez A; Hertzog J; Binz A; Pohlmann A; Prank U; Rehwinkel J; Bauerfeind R; Cristea IM; Pichlmair A; Kochs G; Sodeik B
    Elife; 2022 Apr; 11():. PubMed ID: 35475759
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
    Nicot F; Saliou A; Raymond S; Sauné K; Dubois M; Massip P; Marchou B; Delobel P; Izopet J
    J Clin Virol; 2012 Oct; 55(2):107-13. PubMed ID: 22818969
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A mutation in alpha helix 3 of CA renders human immunodeficiency virus type 1 cyclosporin A resistant and dependent: rescue by a second-site substitution in a distal region of CA.
    Yang R; Aiken C
    J Virol; 2007 Apr; 81(8):3749-56. PubMed ID: 17267487
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected population.
    Pillay D
    Antivir Ther; 2001; 6 Suppl 3():15-24. PubMed ID: 11678470
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Fitness costs of mutations at the HIV-1 capsid hexamerization interface.
    Manocheewa S; Swain JV; Lanxon-Cookson E; Rolland M; Mullins JI
    PLoS One; 2013; 8(6):e66065. PubMed ID: 23785468
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.
    Kozal MJ; Chiarella J; St John EP; Moreno EA; Simen BB; Arnold TE; Lataillade M
    Antivir Ther; 2011; 16(6):925-9. PubMed ID: 21900725
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir.
    Bester SM; Adu-Ampratwum D; Annamalai AS; Wei G; Briganti L; Murphy BC; Haney R; Fuchs JR; Kvaratskhelia M
    mBio; 2022 Oct; 13(5):e0180422. PubMed ID: 36190128
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mechanism of HIV antiretroviral drugs progress toward drug resistance.
    Ammaranond P; Sanguansittianan S
    Fundam Clin Pharmacol; 2012 Feb; 26(1):146-61. PubMed ID: 22118474
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Drug-resistant HIV infection among drug-naive patients in Israel.
    Grossman Z; Lorber M; Maayan S; Bar-Yacov N; Levy I; Averbuch D; Istomin V; Chowers M; Sthoeger Z; Ram D; Rudich H; Mileguir F; Pavel R; Almaliach R; Schlaeffer F; Kra-Oz Z; Mendelson E; Schapiro JM; Riesenberg K
    Clin Infect Dis; 2005 Jan; 40(2):294-302. PubMed ID: 15655750
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance.
    Spira S; Wainberg MA; Loemba H; Turner D; Brenner BG
    J Antimicrob Chemother; 2003 Feb; 51(2):229-40. PubMed ID: 12562686
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evolution and viral characteristics of a long-term circulating resistant HIV-1 strain in a cluster of treatment-naive patients.
    Hofstra LM; Nijhuis M; Pingen M; Mudrikova T; Riezebos-Brilman A; Simoons-Smit AM; Van Ham PM; Bierman WF; Wensing AM
    J Antimicrob Chemother; 2013 Jun; 68(6):1246-50. PubMed ID: 23467175
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
    Simen BB; Simons JF; Hullsiek KH; Novak RM; Macarthur RD; Baxter JD; Huang C; Lubeski C; Turenchalk GS; Braverman MS; Desany B; Rothberg JM; Egholm M; Kozal MJ;
    J Infect Dis; 2009 Mar; 199(5):693-701. PubMed ID: 19210162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.